Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) - Total Liabilities
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) has total liabilities worth CN¥43.19 Billion CNY (≈ $6.32 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Guangzhou Baiyunshan Pharmaceutical Hold to assess how effectively this company generates cash.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd - Total Liabilities Trend (1997–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 600332 financial resilience to evaluate the company's liquid asset resilience ratio.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indian Railway Catering And Tourism Corporation Limited
NSE:IRCTC
|
India | Rs33.71 Billion |
|
Ternium SA DRC
BA:TXR
|
Argentina | AR$7.17 Billion |
|
LG Uplus
KO:032640
|
Korea | ₩10.61 Trillion |
|
Frontdoor Inc
NASDAQ:FTDR
|
USA | $1.90 Billion |
|
OCI Co Ltd
KO:010060
|
Korea | ₩3.21 Trillion |
|
OSI Systems Inc
NASDAQ:OSIS
|
USA | $1.68 Billion |
|
Charoen Pokphand Foods Public Company Limited
BK:CPF
|
Thailand | ฿611.76 Billion |
Liability Composition Analysis (1997–2024)
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guangzhou Baiyunshan Pharmaceutical Hold (600332) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (1997–2024)
The table below shows the annual total liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥43.91 Billion ≈ $6.43 Billion |
+4.78% |
| 2023-12-31 | CN¥41.91 Billion ≈ $6.13 Billion |
+2.15% |
| 2022-12-31 | CN¥41.03 Billion ≈ $6.00 Billion |
+17.93% |
| 2021-12-31 | CN¥34.79 Billion ≈ $5.09 Billion |
+10.26% |
| 2020-12-31 | CN¥31.55 Billion ≈ $4.62 Billion |
+2.11% |
| 2019-12-31 | CN¥30.90 Billion ≈ $4.52 Billion |
+9.05% |
| 2018-12-31 | CN¥28.34 Billion ≈ $4.15 Billion |
+213.08% |
| 2017-12-31 | CN¥9.05 Billion ≈ $1.32 Billion |
+9.80% |
| 2016-12-31 | CN¥8.24 Billion ≈ $1.21 Billion |
+14.70% |
| 2015-12-31 | CN¥7.19 Billion ≈ $1.05 Billion |
+14.95% |
| 2014-12-31 | CN¥6.25 Billion ≈ $914.84 Million |
+19.61% |
| 2013-12-31 | CN¥5.23 Billion ≈ $764.86 Million |
+159.91% |
| 2012-12-31 | CN¥2.01 Billion ≈ $294.28 Million |
+110.34% |
| 2011-12-31 | CN¥956.09 Million ≈ $139.91 Million |
+14.50% |
| 2010-12-31 | CN¥835.05 Million ≈ $122.19 Million |
+1.72% |
| 2009-12-31 | CN¥820.92 Million ≈ $120.13 Million |
-9.39% |
| 2008-12-31 | CN¥905.99 Million ≈ $132.58 Million |
-68.90% |
| 2007-12-31 | CN¥2.91 Billion ≈ $426.22 Million |
+18.63% |
| 2006-12-31 | CN¥2.46 Billion ≈ $359.28 Million |
+7.16% |
| 2005-12-31 | CN¥2.29 Billion ≈ $335.27 Million |
-10.02% |
| 2004-12-31 | CN¥2.55 Billion ≈ $372.62 Million |
+20.63% |
| 2003-12-31 | CN¥2.11 Billion ≈ $308.88 Million |
+20.60% |
| 2002-12-31 | CN¥1.75 Billion ≈ $256.13 Million |
+23.83% |
| 2001-12-31 | CN¥1.41 Billion ≈ $206.85 Million |
-9.71% |
| 2000-12-31 | CN¥1.57 Billion ≈ $229.10 Million |
+2.80% |
| 1999-12-31 | CN¥1.52 Billion ≈ $222.87 Million |
-4.66% |
| 1998-12-31 | CN¥1.60 Billion ≈ $233.77 Million |
-6.08% |
| 1997-12-31 | CN¥1.70 Billion ≈ $248.91 Million |
-- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more